Primary hyperparathyroidism in women: Medical and surgical treatments

Jennifer Wojtowicz, Mira Milas

Research output: Contribution to journalArticlepeer-review


Primary hyperparathyroidism (HPT) occurs in 2% of people over the age of 55. Women are affected two to three times more often then men. Postmenopausal women are at the greatest risk. The advent of the multichannel, routine screening of serum chemistries in the 1970s led to a dramatic increase in the detection of hypercalcemia and the diagnosis of underlying HPT. The recognition of HPT and its evolving clinical presentation has also been influenced by greater attention devoted over the last two decades to the screening for bone disease. Chronic parathyroid hormone excess stimulates bone remodeling and ultimately activates osteoclast-mediated destruction of bone. Medical treatment options are evolving for osteoporosis in HPT. Treatments that may improve bone density in HPT include bisphosphonates, estrogen, selective estrogen receptor modulators, and surgery.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalClinical Reviews in Bone and Mineral Metabolism
Issue number2
StatePublished - Jun 2005


  • Bisphosphonates
  • Hyperparathyroidism
  • Osteoporosis
  • Postmenopausal
  • Selective estrogen receptor modulators (SERMs) parathyroidectomy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology


Dive into the research topics of 'Primary hyperparathyroidism in women: Medical and surgical treatments'. Together they form a unique fingerprint.

Cite this